Anti-pig antibody in infants: can a genetically-engineered pig heart bridge to allotransplantation?

Publication date: Available online 30 September 2019Source: The Annals of Thoracic SurgeryAuthor(s): Qi Li, Hidetaka Hara, C. Adam Banks, Takayuki Yamamoto, David Ayares, David C. Mauchley, Robert J. Dabal, Luz Padilla, Waldemar F. Carlo, Leslie A. Rhodes, David K.C. Cooper, David C. ClevelandABSTRACTBackgroundCongenital heart patients have high heart-transplant waitlist mortality, and mechanical support is suboptimal. To evaluate feasibility of cardiac grafts from a genetically-engineered triple-knockout pig as a bridge to allotransplantation, preformed anti-pig antibodies were measured in pediatric and adult patients.MethodsFlow cytometry measured serum IgM/IgG binding to wild-type and triple-knockout red blood cells (RBCs), with binding to human O-negative RBCs as a negative control. Group 1: 84 pediatric patients and 64 healthy adults’ sera with no previous cardiac surgery. Group 2: 25 infant’s sera post-cardiac surgery, including 10 after palliation for hypoplastic left heart syndrome.ResultsGroup 1: IgM binding to wild-type RBCs occurred in 80% and IgG binding in 91% sera. Only 3% sera showed IgM binding to triple-knockout RBCs, and one (
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research

Related Links:

Condition:   Acute Rejection of Cardiac Transplant Intervention:   Diagnostic Test: INNOGRAFT Heart Suite Sponsors:   Myway Gentics Srl;   Policlinico San Matteo Pavia Fondazione IRCCS;   Istituto Di Ricerche Farmacologiche Mario Negri Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This article describes the studies that have been conducted to date and emphasises that mortality after stem cell transplant (not attributed to CMV end-organ disease) has recently become the first proven indirect effect of CMV now that letermovir has significantly reduced non-relapse deaths.The implications for CMV vaccines are then discussed. Vaccines are already predicted to be highly cost-effective if they can reduce CMV end-organ disease. Health planners should now consider that cost effectiveness is likely to be enhanced further through reduction of the indirect effects of CMV. A prototype scheme for assessing this po...
Source: Antiviral Therapy - Category: Virology Source Type: research
ConclusionsOur data suggest that GLP-1RA do not affect tacrolimus levels or transplant outcomes in solid organ transplant (SOT) recipients in the short term. GLP-1RA also seem to be as effective in SOT recipients for glycemic control and weight loss as in the non-transplant population with diabetes.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
AbstractThe first successful human heart transplantation was reported on 3 December 1967, by Christiaan Barnard in South Africa. Since then this life ‐saving procedure has been performed in over 120 000 patients. A limitation to the performance of this procedure is the availability of donor hearts with as many as 20% of patients dying before a donor's heart is available for transplant. Today, hearts for transplantation are procured from indiv iduals experiencing donation after brain death (DBD). Interestingly, this, however, was not always the case as the first heart transplants occurred after circulatory dea...
Source: Journal of Cardiac Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: REVIEW ARTICLE Source Type: research
This is the latest in a series of yearly posts in which I suggest areas of development for biotech startups I'd like to see actively developed as a part of the longevity industry in the near future. Today, this year, is a good time to be starting a company focused on the production of a novel therapeutic approach to intervening in the aging process. There is a great deal of funding for seed stage investment, and many compelling projects lacking champions, yet to be carried forward from academia into preclinical development. Numerous scientific and industry crossover conferences are now held every year, at which it is possi...
Source: Fight Aging! - Category: Research Authors: Tags: Investment Source Type: blogs
The Life Extension Advocacy Foundation volunteers here interview Hanadie Yousef of Juvena Therapeutics. Her team is mining the secretions of pluripotent stem cells to find factors that can improve regeneration and stem cell activity in older individuals. Juvena represents one small slice of a broad trend in the regenerative medicine community, many teams building on the past decades of work on stem cell transplantation by seeking to understand and manipulate the cell signaling thought to produce benefits in patients undergoing these first generation therapies. In near all such stem cell therapies, the transplanted cells di...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
Since the publication of its first Core Cardiovascular Training Statement (COCATS) in 1995,1 the American College of Cardiology (ACC) has defined the knowledge, experiences, skills, and behaviors expected of clinical cardiologists. Subsequent revisions have moved toward competency-based training based on the 6-domain competency structure promulgated by the Accreditation Council for Graduate Medical Education (ACGME) and the American Board of Medical Specialties and endorsed by the American Board of Internal Medicine (ABIM).
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Tags: LIFELONG LEARNING STATEMENT Source Type: research
Discussion of the Evolutionary Genetics of Aging Thymic Involution Contributes to Immunosenescence and Inflammaging The Potential for Exosome Therapies to Treat Sarcopenia Correlations of Mitochondrial DNA Copy Number and Epigenetic Age Measures Evidence for PASK Deficiency to Reduce the Impact of Aging in Mice The Aging Retina, a Mirror of the Aging Brain Evidence for Loss of Capillary Density to be Important in Heart Disease Aspects of Immune System Aging Proceed More Rapidly in Men Deacetylation of the NLRP3 Inflammasome as a Way to Control Chronic Inflammation Transplantation of Senescent Cells is an ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
We describe a patient who presented with congestive heart failure that required a left ventricular assist device and a temporary right ventricular assist device along with immunosuppressive therapy. This case also brings to attention how undocumented immigration status can limit transplantation opportunities in the USA.
Source: Journal of Cardiology Cases - Category: Cardiology Source Type: research
We report central invasive haemodynamic parameters at rest and exercise during a 3 year follow‐up after HTx in a sub‐study of the SCandiavian Heart transplant Everolimus De novo stUdy with earLy calcineurin inhibitor avoidancE trial. We hypothesized that the nephroprotective properties, the less development of cardiac allograft vasculopathy (CAV), and the antifibrotic properties of EVR, in comparison with CNI‐based immunosuppression, would demonstrate favourable invasive haemodynamic profiles in patients at rest and during exercise.Methods and resultsNinety of 115 HTx recipients randomized to EVR or CNI treatment per...
Source: ESC Heart Failure - Category: Cardiology Authors: Tags: Original Research Article Source Type: research
More News: Cardiology | Cardiovascular & Thoracic Surgery | Genetics | Heart | Heart Transplant | Pediatrics | Transplant Surgery | Transplants